About: Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.88 (+0.21%)
CING NASDAQ Cingulate Inc
Cingulate Inc share price
CING price activity
Last Price
$4.880
Change (24hr)
0.01 USD (0.21%)
Volume
74.85K
Volume (4w avg)
-
Open
$4.84
Day Range
$4.75 - $4.98
Previous Close
$4.87
Last Trade
08 Oct, 8:00 pm GMT+0
Delayed
08 Oct, 8:00 pm GMT+0
CING price performance
Delayed
08 Oct, 8:00 pm GMT+0
CING Market Signals